Bank of America raises target for Sino Biopharm stock to HKD 7.40

Published on 10/17/2026 at 18:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AASLD presentations are scheduled for November 7 and 8, 2026. Sino Biopharm stock costs HKD 5.25 on October 16, 2026, down 0.38 percent on HKEX.

Analyst target and market dates

Bank of America Securities raised its target from HKD 7.30 to HKD 7.40 on October 2, 2026.
Sino Biopharmaceutical has presentations scheduled for November 7 and November 8, 2026.
Sino Biopharm stock closed at HKD 5.25 on October 16, 2026, down 0.38 percent on HKEX versus the prior close.
Market capitalization stood at HKD 93.5 billion, with a P/E ratio of 33.78.

Sino Biopharm, KYG8167W1380, Illustration mit AI erstellt.

Bank of America Securities raised its Sino Biopharm target from HKD 7.30 to HKD 7.40 and reaffirmed its Buy rating on October 2, 2026, according to Futubull. The revised target stood 40.95 percent above the HKEX closing price of HKD 5.25 on October 16, 2026. Sino Biopharm stock closed at HKD 5.25 on October 16, 2026, down 0.38 percent from the prior HKEX close.

Clinical dates arrive in November

Sino Biopharmaceutical's hepatitis B portfolio has two scheduled oral presentations at the American Association for the Study of Liver Diseases meeting. Flcube reported that bepirovirsen results are scheduled for November 7, 2026, while TQ-A3334 data are scheduled for November 8, 2026.

How far is the stock from its high?

The HKEX price sits within a 52-week range of HKD 4.19 to HKD 7.56. At HKD 5.25, the stock was 30.56 percent below the 52-week high and 25.30 percent above the 52-week low. Trading volume reached 83,811,981 shares against an average of 77,557,713 shares on October 16, 2026.

Valuation and interim figures

Sino Biopharm had a market capitalization of HKD 93.5 billion, a P/E ratio of 33.78 and a dividend yield of 0.02 percent on October 16, 2026. In the first half of 2026, revenue reached RMB 19.44 billion, up 10.60 percent year over year, while profit attributable to equity holders rose 1.40 percent to RMB 3.43 billion, according to Futubull on September 24, 2026.

Comparison with peers

Sino Biopharm (HKEX, HKD): minus 0.38 percent, P/E 33.78, market capitalization HKD 93.5 billion.
Sinopharm Group (HKEX, HKD): plus 0.45 percent, P/E 5.94, market capitalization HKD 49.1 billion.
WuXi Biologics (HKEX, HKD): minus 0.90 percent, P/E 34.45, market capitalization HKD 198.4 billion.

Price remains below the yearly high

The October 16, 2026 close leaves the stock closer to its yearly high than its yearly low in absolute price terms, while the analyst target remains above the latest HKEX level.

Market context: Current market reports.

More news and analyses on Sino Biopharm stock